110 related articles for article (PubMed ID: 8178066)
1. [Therapeutic prospects in autoimmunity].
Revillard JP
Rev Prat; 1994 Jan; 44(1):93-7. PubMed ID: 8178066
[TBL] [Abstract][Full Text] [Related]
2. [The current and future outlook in immunosuppressive therapy for children].
Goţia S; Ionescu C
Rev Med Chir Soc Med Nat Iasi; 1995; 99(1-2):35-42. PubMed ID: 9524654
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy in non-allergic diseases].
Español T
Allergol Immunopathol (Madr); 2000; 28(3):107-9. PubMed ID: 10867379
[TBL] [Abstract][Full Text] [Related]
4. [Autoimmune dermatoses: new therapeutic strategies].
Trüeb RM
Praxis (Bern 1994); 2000 Sep; 89(37):1460-7. PubMed ID: 11037617
[TBL] [Abstract][Full Text] [Related]
5. Immune therapies of autoimmune diseases: are we approaching a real cure?
Chatenoud L
Curr Opin Immunol; 2006 Dec; 18(6):710-7. PubMed ID: 17011768
[TBL] [Abstract][Full Text] [Related]
6. Trends in the development of therapeutic anti-cytokine antibodies.
Reichert JM
Drug Discov Today; 2004 Apr; 9(8):348. PubMed ID: 15081960
[No Abstract] [Full Text] [Related]
7. [New methods of therapy for ocular inflammatory autoimmune diseases].
Kubicka-Trzaska A; Undas A
Klin Oczna; 2003; 105(6):428-32. PubMed ID: 15049272
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with cytokines in autoimmune diseases.
Delavallée L; Assier E; Denys A; Falgarone G; Zagury JF; Muller S; Bessis N; Boissier MC
Ann Med; 2008; 40(5):343-51. PubMed ID: 18484346
[TBL] [Abstract][Full Text] [Related]
9. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
Rütter A; Luger TA
J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
[TBL] [Abstract][Full Text] [Related]
10. Treatment of autoimmune disease: synergy between plasma exchange and intravenous immunoglobulins.
Nydegger UE; Sturzenegger T
Ther Apher; 2001 Jun; 5(3):186-92. PubMed ID: 11467755
[TBL] [Abstract][Full Text] [Related]
11. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.
Beyersdorf N; Hanke T; Kerkau T; Hünig T
Autoimmun Rev; 2006 Jan; 5(1):40-5. PubMed ID: 16338210
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases].
Mouthon L; Hurez V; Kazatchkine M
Ann Med Interne (Paris); 1993; 144(8):506-13. PubMed ID: 8179238
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory and autoimmune complications of common variable immune deficiency.
Knight AK; Cunningham-Rundles C
Autoimmun Rev; 2006 Feb; 5(2):156-9. PubMed ID: 16431351
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy of autoimmune diseases.
Bach JF
Immunol Today; 1993 Jun; 14(6):322-6. PubMed ID: 8104411
[TBL] [Abstract][Full Text] [Related]
16. [Biological response modifiers in the treatment of immunoinflammatory diseases].
Skov L; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2120-6. PubMed ID: 18565292
[TBL] [Abstract][Full Text] [Related]
17. [High dose intravenous immunoglobulins in therapeutic arsenal in autoimmune and systemic diseases].
Klein M; Kaminsky P; Duc M
Therapie; 1993; 48(2):97-103. PubMed ID: 8351694
[TBL] [Abstract][Full Text] [Related]
18. Targeting T regulatory cells in autoimmune diseases.
Toubi E
Isr Med Assoc J; 2008 Jan; 10(1):73-6. PubMed ID: 18300580
[TBL] [Abstract][Full Text] [Related]
19. Animal models of systemic vasculitis.
Mathieson PW; Qasim FJ; Esnault VL; Oliveira DB
J Autoimmun; 1993 Apr; 6(2):251-64. PubMed ID: 8388693
[TBL] [Abstract][Full Text] [Related]
20. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin.
Jayne DR; Esnault VL; Lockwood CM
J Autoimmun; 1993 Apr; 6(2):207-19. PubMed ID: 8499059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
